A Fortune 500 retailer cut robot idle time by 15%, replenishment cycles by 12%, and costs by 8% in two months. Most ...

"Neumora’s Alzheimer’s disease agitation drug shows early success in Phase Ib trial" was originally created and published by ...

This is your everyday lunar guidance. The Moon moves from Krishna Paksha Tritiya to Chaturthi at 8:01 AM, entering a deeper ...

Milwaukee will raise downtown parking rates by $0.50/hour and other areas by $0.25/hour starting in early 2026.

At its Dec. 16 meeting, the Jackson City Council unanimously approved the final change order for Phase 1A, authorizing an ...

Developers in Bend are scaling back the vision for a massive urban neighborhood planned near the Old Mill District and the ...

New name to reflect recent transformative acquisition of rights to Phase 3 program in metastatic breast cancer and commitment to continued leadership, resilience and innovation ...

Spotify is betting loyalty beats virality. Earlier payouts, easier distribution, and new video sponsorship tools reveal the ...

In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonst ...

Super Micro Computer's stock trades at a deep discount, but a strong backlog and execution catalysts suggest asymmetric ...

Weight-loss experts reveal their major predictions for 2026, from advanced GLP-1 treatments to AI-driven personalized therapy ...

The Phase 1b trial consisted of 24 patients with Parkinson’s disease, who received twice-weekly dosing of either HER-096 or placebo over a four-week period. The trial’s exploratory biomarker program ...